CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 18 enrolled
Drug / intervention
RUL ECT +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01869374
NCT01869374Phase 2Completed

Improving Outcomes in Geriatric Depression: Magnetic Seizure Therapy

New York State Psychiatric Institute·interventional·Posted Jun 5, 2013·Updated Sep 3, 2020

In Brief

A Phase 2 clinical trial evaluating MagVenture MagPro MST and RUL ECT for Depression and 2 related conditions. Completed, enrolled 18 participants across 1 site.

Detailed Summary

To evaluate the feasibility, tolerability and efficacy of Magnetic Seizure Therapy (MST) in elderly patients with a major depressive episode, who are randomly assigned to receive an acute course of MST or ECT. The investigators hypothesize: 1. MST and ECT will have similar antidepressant efficacy 2. MST will have less post-treatment amnesia than ECT as reflected in a primary measures of anterograde and retrograde amnesia following the acute treatment phase. 3. At follow up, MST will show a lesser degree of persisting deficit in measures of retrograde amnesia than ECT.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJun 5, 2013
Enrollment StartAug 1, 2012
Primary CompletionJul 1, 2017
Study CompletionAug 1, 2020
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 13.1 years ago

Interventions

MagVenture MagPro MSTdevice

Brain stimulation by magnetic means versus electrical standard unilateral Electroconvulsive Therapy (RUL ECT). Treatment will be administered 3 times a week.

RUL ECTbiological

RUL ECT using the Somatics Thymatron device with Ultrabrief stimulus. Treatment will be administered 3 times a week.